Form D · Biotechnology
Cellics Therapeutics, Inc.
San Diego, CA · CIK 0001611752
Offering snapshot reported Feb 17, 2022 · SEC filing
- Reported sold
- $7M Offering amount: $25M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 8, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 17, 2022 | Initial | $6,999,995 | No comparison | 1 | SEC filing |
| Jun 9, 2020 | Initial | $13,000,635 | No comparison | 3 | SEC filing |
| Apr 23, 2018 | Initial | $6,999,983 | No comparison | 4 | SEC filing |
| Apr 21, 2017 | Amendment | $6,000,050 | $3,000,025vs Feb 8, 2016 | 1 | SEC filing |
| Feb 8, 2016 | Initial | $3,000,025 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-434042
Source: Form D, filed Feb 17, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Angela Fang Chen | Director |
| Weiwei Gao | Director |
| Dai Jimming | Director |
| Dai Jinming | Director |
| Cihui Li | Director |
| Wei Shen | Director |
| Lili Xie | Executive |
| Jie Zhang | Director, Executive |
| Liangfang Zhang | Director |
| Huiqing Zhu | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11588 Sorrento Valley Road Suite #20
San Diego, CA, 92121
San Diego, CA, 92121